Loading stock data…
Nuvation Bio Inc. (NUVB)
$6.61-0.20 (-2.94%)
Market ClosedLast close Sep 8
Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on developing product candidates for cancer treatment.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Nuvation Bio Inc. in the Healthcare sector is trading at $6.61 with a market capitalization of $2.4B. Wall Street consensus targets $13.10 (10 analysts), implying a +98.2% move over the next 12 months. The stock is currently 32% below its 52-week high of $9.75, remaining 10.9% above its 200-day moving average. On fundamentals, Piotroski 4/9 shows mixed financial quality. The Whystock Score of 95/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +98.2% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $31.69M↓ | $83.23M↑ | $41.87M↑ | $13.12M↑ | $4.83M |
| Gross Profit | $22.22M↓ | $77.24M↑ | $40.59M↑ | $9.77M↑ | $2.26M |
| Operating Income | -$51.04M↓ | $3.88M↑ | -$34.04M↑ | -$56.43M↑ | -$63.59M |
| Net Income | -$62.84M↓ | $5.40M↑ | -$36.59M↑ | -$55.79M↑ | -$59.01M |
Peer Comparison
JNJUNHPFE
Fundamentals
Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on developing product candidates for cancer treatment. The company's lead product candidate is IBTROZI (taletrectinib), a ROS1 inhibitor for the treatment of patients with ROS1+ n...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$2.39B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.53
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-59.02%
Volume
Today's trading volume
2.54M
Recent News
Jim Cramer sends strong 5-word message on surging biotech stock
Cramer flagged the company as too risky for most people, even as the stock climbs on real medical news.
Does Nuvation Bio (NUVB) Have the Potential to Rally 91.92% as Wall Street Analysts Expect?
The average of price targets set by Wall Street analysts indicates a potential upside of 91.9% in Nuvation Bio (NUVB). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Nuvation Bio (NUVB) Upgraded to Buy: Here's Why
Nuvation Bio (NUVB) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
JPMorgan sees 100% upside in overlooked cancer drug stock
The bank just put a big number on a small biotech company, and the target rests on a newly launched drug.
Wall Street Analysts Predict a 105.71% Upside in Nuvation Bio (NUVB): Here's What You Should Know
The mean of analysts' price targets for Nuvation Bio (NUVB) points to a 105.7% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.